Thyroid Disease in Pregnancy: Screening and Treatment Targets
Clinical Practice Update — Who to test, when to treat, which TSH target to aim for, and what the 2026 ATA guideline changed for obstetric care
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Screening strategy, diagnostic thresholds, levothyroxine and antithyroid drug targets, and postpartum follow-up for thyroid disease in pregnancy
- Target Audience
- Obstetricians, maternal-fetal medicine specialists, endocrinologists, family physicians, midwives, residents
- Setting
- Preconception clinics, antenatal clinics, fertility services, postpartum care
- Source Evidence
- •American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum (Thyroid, 2026)
- •ACOG Practice Bulletin No. 223 — Thyroid Disease in Pregnancy (Obstet Gynecol, 2020)
- •RCOG Green-top Guideline No. 76 — Management of Thyroid Disorders in Pregnancy (BJOG, 2025)
- •CATS trial (NEJM, 2012) and MFMU Network levothyroxine trial (NEJM, 2017)
- •TABLET trial — Levothyroxine in TPO antibody-positive women (NEJM, 2019)
What Changed in Practice
The 2026 American Thyroid Association guideline, endorsed by ACOG, reshapes how thyroid disease in pregnancy is found and treated, replacing reflexive levothyroxine with confirmed, trimester-aware decisions.1
Key Clinical Takeaways
Direct actions for thyroid disease in pregnancy, most practice-changing first.
- 1Retest a mildly raised TSH (below 6 mU/L) within about three weeks before committing to levothyroxine, using shared decision-making → When Should Subclinical Hypothyroidism Be Treated?
- 2Stop prescribing levothyroxine to euthyroid TPO antibody-positive women for miscarriage or IVF outcomes → What About TPO Antibodies and Euthyroid Women?
- 3Tell every woman on levothyroxine to increase her dose herself — two extra tablets a week — as soon as a pregnancy test is positive → How Should Known Hypothyroidism Be Managed?
- 4Switch women on methimazole to propylthiouracil once they are actively trying to conceive → How Should Graves Disease Be Managed?
- 5Test TSH only in women with risk factors, not in every pregnant patient → Who Should Be Tested for Thyroid Disease in Pregnancy?
- 6Measure TRAb or TSI in the first trimester in anyone with a history of Graves disease, including after ablation → How Should Graves Disease Be Managed?
- 7Leave gestational transient thyrotoxicosis untreated with antithyroid drugs → Is a Low TSH Always Hyperthyroidism?
Why This Update Matters
Thyroid disease in pregnancy is common enough that every antenatal clinic sees it weekly: subclinical hypothyroidism affects about 3–3.5% of pregnancies and TPO antibodies about 9%.1 The old “treat anything above 2.5” habit left many women on lifelong levothyroxine for a transient result. The new approach protects the fetal brain where the evidence supports it — overt hypothyroidism, early-pregnancy subclinical disease, Graves antibodies — while sparing the rest from unnecessary tablets, anxiety and extra visits.
Who Should Be Tested for Thyroid Disease in Pregnancy?
ACOG and the ATA both reject universal screening for thyroid disease in pregnancy, because finding and treating subclinical hypothyroidism has not improved outcomes.1,2 The ATA has refined its risk-factor list instead, validated in commissioned cohorts.1
Do not perform universal thyroid function screening in pregnancy, preconception or postpartum.
AgainstHigh EvidenceACOG PB 223 2020ATA 2026Evaluate every newly pregnant patient clinically for thyroid risk factors and offer TSH testing, ideally in the first trimester, to those at increased risk. Practice impact: build the risk-factor checklist into the booking visit rather than ordering TSH by habit.
Strong RecModerate EvidenceATA 2026RCOG GTG 76 2025Test women with known thyroid antibodies, personal or family history of thyroid disease, type 1 diabetes or other autoimmune disease, prior neck radiation or thyroid surgery, Down or Turner syndrome, thyroid-active medications such as amiodarone or lithium, or likely iodine deficiency.
Strong RecModerate EvidenceATA 2026ACOG PB 223 2020Test women with infertility or recurrent miscarriage if this was not done before conception.
Moderate RecLow EvidenceATA 2026Measure TSH first, reflexing to free T4 when TSH is abnormal, and add total T3 when hyperthyroidism is suspected.
Strong RecHigh EvidenceACOG PB 223 2020Avoid routine TPO antibody screening in euthyroid women without risk factors.
AgainstModerate EvidenceACOG PB 223 2020What TSH Threshold Defines Hypothyroidism?
The biggest conceptual shift in thyroid disease in pregnancy is the explicit separation of diagnostic thresholds from treatment targets. The old 2.5 and 3.0 mU/L limits, used diagnostically, labelled many healthy women hypothyroid.1,12 In thyroid disease in pregnancy, TSH remains the most reliable marker because free T4 immunoassays drift with the binding-protein changes of pregnancy.1
Use laboratory- and trimester-specific TSH and free T4 reference intervals wherever they exist.
Strong RecModerate EvidenceATA 2026RCOG GTG 76 2025Consider a first-trimester TSH range of about 0.1–4.0 mU/L when local pregnancy ranges are unavailable; where the non-pregnant upper limit is well above 4.5 mU/L, subtract 0.5 mU/L instead. Practice impact: stop diagnosing hypothyroidism at a TSH of 2.6–4.0 mU/L.
Moderate RecLow EvidenceATA 2026Prioritise TSH over free T4 when they conflict, and keep the same assay throughout.
Strong RecModerate EvidenceATA 2026How Should Known Hypothyroidism Be Managed?
Pre-existing hypothyroidism is the commonest thyroid disease in pregnancy seen in clinic. Women who are euthyroid on levothyroxine have fertility and pregnancy outcomes similar to women without hypothyroidism, so the job is to stay ahead of rising demand.1 Requirement typically climbs about 25% by week 12 and about 50% by week 20.1,9
Aim for a preconception TSH of 0.5–2.5 mU/L in women on levothyroxine who are planning pregnancy.
Moderate RecLow EvidenceATA 2026ACOG PB 223 2020Counsel women to self-initiate a dose increase as soon as the pregnancy test is positive — two extra daily doses per week, or a roughly 25% daily increase. Practice impact: give the instruction in writing at the preconception visit so the increase is not delayed until booking.
Strong RecModerate EvidenceRCOG GTG 76 2025ATA 2026Temper the empirical increase when preconception TSH is below 1.5 mU/L or the dose exceeds 100 mcg/day, where overtreatment is more likely.
Conditional RecLow EvidenceATA 2026Target a TSH within the pregnancy reference range and below 2.5 mU/L during pregnancy.
Strong RecModerate EvidenceACOG PB 223 2020ATA 2026Switch women taking liothyronine or desiccated thyroid to levothyroxine monotherapy before conception, because the fetal brain depends on maternal T4.
Strong RecLow EvidenceATA 2026ACOG PB 223 2020Anticipate an earlier or larger increase after ovarian stimulation for IVF and in twin pregnancies.
Conditional RecLow EvidenceATA 2026Return to the prepregnancy dose at delivery and recheck thyroid function at six weeks.
Moderate RecLow EvidenceATA 2026When Should Overt Hypothyroidism Be Treated?
Overt hypothyroidism is the form of thyroid disease in pregnancy with the clearest case for treatment. It is associated with miscarriage, gestational hypertension, preterm birth and lower offspring IQ, and treatment to euthyroidism appears to remove most of that excess risk.1,2
Start levothyroxine for overt hypothyroidism with TSH at or above 6 mU/L.
Strong RecModerate EvidenceATA 2026ACOG PB 223 2020Estimate the starting dose as full replacement (1.5–1.7 mcg/kg/day) plus a further 20–30% for pregnancy.
Moderate RecLow EvidenceATA 2026Consider retesting mild overt hypothyroidism (TSH above the pregnancy limit but below 6 mU/L) within one to three weeks before starting treatment, if the patient prefers after counselling. Practice impact: mild overt disease is now handled much like subclinical disease rather than as an automatic prescription.
Conditional RecLow EvidenceATA 2026When Should Subclinical Hypothyroidism Be Treated?
This is where thyroid disease in pregnancy practice has changed most. CATS (treatment from a median of about 12 weeks) and the MFMU trial (about 17 weeks) showed no gain in child IQ or obstetric outcomes.5,6 A smaller trial treating mostly in the first trimester suggested fewer preterm births, but only with a TSH cut-off above 4.0 mU/L.1
Offer levothyroxine through shared decision-making for subclinical hypothyroidism found in the first trimester, explaining both the modest risks and the uncertain benefit.
Conditional RecLow EvidenceATA 2026Consider retesting within about three weeks before treating, especially when TSH is below 6 mU/L; if treatment is deferred, recheck within three weeks to exclude progression.
Conditional RecLow EvidenceATA 2026Start a low dose of 25–75 mcg/day, guided by TSH and weight, if treating. Practice impact: avoid fixed high doses — overtreated CATS participants had children with more ADHD-type symptoms.
Moderate RecLow EvidenceATA 2026Avoid routinely starting levothyroxine for subclinical hypothyroidism first found after the first trimester.
AgainstHigh EvidenceCATS 2012MFMU 2017ATA 2026Postpone conception and repeat TSH after four to six weeks when subclinical hypothyroidism is found before pregnancy; start around 50 mcg/day if it persists or waiting is impractical.
Moderate RecLow EvidenceATA 2026Plan a levothyroxine cessation trial after delivery for women treated only for subclinical disease.
Moderate RecLow EvidenceATA 2026Matching the Result to the Action
| TSH Result (with Normal or Low Free T4) | Found Preconception | Found in First Trimester | Found After First Trimester |
|---|---|---|---|
| Above pregnancy limit, below 6 mU/L, normal free T4 | Delay conception, retest in 4–6 weeks | Shared decision; retest in about 3 weeks or start 25–75 mcg | Do not start routinely; manage expectantly |
| Above pregnancy limit, below 6 mU/L, low free T4 | Treat and titrate to 0.5–2.5 mU/L | Retest in 1–3 weeks or treat, per preference | Treat |
| 6 mU/L or higher, normal free T4 | Low-dose levothyroxine without waiting | Shared decision, lean toward treating | Individualise; evidence of benefit is weak |
| 6 mU/L or higher, low free T4 | Treat | Treat promptly with weight-based dose | Treat promptly with weight-based dose |
| Normal TSH, TPOAb positive | No levothyroxine; recheck TSH every 3–6 months | No levothyroxine; follow TSH through pregnancy | No levothyroxine |
What About TPO Antibodies and Euthyroid Women?
In thyroid disease in pregnancy, antibody-positive euthyroid women carry a small excess risk of miscarriage (about 2–8% absolute) and preterm birth, but three high-quality randomised trials — including TABLET in women with prior miscarriage or infertility and a Chinese IVF trial — found no benefit from levothyroxine.1,7,8 The likely explanation is that antibodies mark a wider autoimmune tendency rather than a thyroid hormone deficit.1
Do not prescribe levothyroxine to euthyroid TPOAb-positive women, including those with infertility, IVF or recurrent miscarriage. Practice impact: discontinue “just in case” levothyroxine started for antibodies alone.
AgainstHigh EvidenceTABLET 2019ATA 2026Recheck TSH every three to six months before conception in antibody-positive women, and follow thyroid function through pregnancy, since about 18% develop subclinical hypothyroidism in pregnancy.
Moderate RecModerate EvidenceATA 2026Do not use selenium, corticosteroids or intravenous immunoglobulin to improve outcomes in antibody-positive women.
AgainstLow EvidenceATA 2026Is a Low TSH Always Hyperthyroidism?
A suppressed TSH at the end of the first trimester is usually physiology rather than thyroid disease in pregnancy: hCG stimulates the TSH receptor, and a TSH below 0.4 mU/L is common in healthy pregnancy.1 Gestational transient thyrotoxicosis resolves as hCG falls and has not been linked to poor outcomes.2
Do not treat gestational transient thyrotoxicosis with antithyroid drugs; manage fluids and vomiting instead.
AgainstModerate EvidenceACOG PB 223 2020ATA 2026Do not check thyroid function routinely in hyperemesis gravidarum unless signs of overt hyperthyroidism are present.
AgainstLow EvidenceACOG PB 223 2020Repeat thyroid function every two to four weeks for a low TSH with normal free T4 and T3 until TSH normalises.
Moderate RecLow EvidenceATA 2026Measure TRAb or TSI when overt hyperthyroidism persists, particularly beyond 20 weeks.
Strong RecModerate EvidenceATA 2026Do not treat subclinical hyperthyroidism in pregnancy.
AgainstModerate EvidenceACOG PB 223 2020How Should Graves Disease Be Managed?
Graves disease accounts for about 95% of hyperthyroidism in pregnancy — the most consequential hyperthyroid form of thyroid disease in pregnancy — and poor control raises the risk of pre-eclampsia, heart failure, thyroid storm, growth restriction and stillbirth.2 Both thioamides are teratogenic, but methimazole defects (aplasia cutis, choanal and oesophageal atresia) are more severe.10,11
Discuss pregnancy plans with every woman of reproductive age newly diagnosed with Graves disease, and advise waiting to conceive until euthyroid on two sets of tests at least six weeks apart.
Moderate RecLow EvidenceATA 2026Switch methimazole to propylthiouracil once actively trying to conceive; if propylthiouracil is unavailable, use the lowest effective methimazole dose. Practice impact: make the switch at the planning visit, not after the first missed period.
Strong RecModerate EvidenceATA 2026ACOG PB 223 2020Consider stopping antithyroid drugs at pregnancy confirmation in women euthyroid on a low dose after at least six months of therapy, with close thyroid monitoring.
Conditional RecLow EvidenceATA 2026Titrate to the lowest thioamide dose that keeps free T4 at or slightly above the upper part of the pregnancy reference range, regardless of TSH.
Strong RecModerate EvidenceACOG PB 223 2020ATA 2026Measure TRAb or TSI in the first trimester in all women with a Graves history — including after radioiodine or thyroidectomy — and repeat at 18–22 weeks if above three times the upper limit.
Strong RecModerate EvidenceATA 2026Arrange serial fetal ultrasound from 18–20 weeks when antibodies stay high or antithyroid drugs continue, looking for tachycardia, growth restriction, goitre or hydrops.
Moderate RecLow EvidenceATA 2026ACOG PB 223 2020Avoid radioiodine in pregnancy, and delay conception for at least six months after it.
Strong RecModerate EvidenceATA 2026Reserve thyroidectomy in pregnancy for failure or intolerance of drugs, preferring the second trimester and a high-volume surgeon.
Moderate RecLow EvidenceATA 2026Notify the paediatric team of maternal Graves disease and antibody status before delivery.
Strong RecLow EvidenceACOG PB 223 2020Drugs Used in Thyroid Disease in Pregnancy
Doses below are guideline-based starting points for thyroid disease in pregnancy; titration and the choice to switch agents after the first trimester usually involve endocrinology or maternal-fetal medicine and follow local protocol.
| Drug | Indication | Dose (guideline-based) | Target / Monitoring | Major Adverse Effects | Practical Notes |
|---|---|---|---|---|---|
| Levothyroxine | Overt or selected subclinical hypothyroidism | New overt: 1.5–1.7 mcg/kg/day plus 20–30%; subclinical: 25–75 mcg/day; known disease: +2 doses/week at positive test | TSH in pregnancy range and below 2.5 mU/L; every 4 weeks to mid-gestation | Iatrogenic hyperthyroidism if overtreated | Separate from iron and calcium; back to prepregnancy dose at delivery |
| Propylthiouracil | Hyperthyroidism, preconception and first trimester | 100–600 mg/day in three divided doses; typical 200–400 mg | Free T4 at upper end of pregnancy range; every 2–4 weeks | Hepatotoxicity; agranulocytosis | Converts to methimazole at about 20:1 if switched |
| Methimazole | Hyperthyroidism after the first trimester | 5–30 mg/day, once daily in maintenance | As for propylthiouracil | First-trimester embryopathy; agranulocytosis | Switching mid-pregnancy may briefly worsen control |
Clinical Decision Pathway
A question-based route through thyroid disease in pregnancy.
Who Needs a Different Approach?
Several groups need the standard framework for thyroid disease in pregnancy adjusted rather than replaced. Iodine-poor or plant-based diets raise the risk of maternal and fetal hypothyroidism, and amiodarone or iodinated contrast delivers an iodine load that can disturb fetal thyroid function, so weigh these carefully before use.1
Advise iodine 150 mcg daily for all women from at least three months before conception through lactation, aiming for a total intake of about 250 mcg/day. Practice impact: check that the prenatal vitamin actually contains iodine — many do not.
Moderate RecLow EvidenceATA 2026Avoid iodine supplements above 500 mcg daily in pregnancy.
AgainstLow EvidenceATA 2026Evaluate for fetal thyrotoxicosis and involve maternal-fetal medicine when a Graves history coexists with fetal tachycardia, growth restriction, goitre or hydrops.
Strong RecLow EvidenceACOG PB 223 2020Treat suspected thyroid storm immediately in a high-dependency setting without waiting for results, using propylthiouracil, iodine given 1–2 hours later, a glucocorticoid and cautious beta-blockade.
Strong RecLow EvidenceACOG PB 223 2020Monitoring Thyroid Disease in Pregnancy and Postpartum
Monitoring is where good management of thyroid disease in pregnancy is either sustained or lost, and the postpartum year is part of thyroid disease in pregnancy care, not an afterthought. Postpartum thyroiditis affects about 5–10% of women, usually as brief thyrotoxicosis then hypothyroidism at four to eight months; a third develop permanent hypothyroidism.2 Graves disease in remission relapses after delivery in about 25–55%.1
Check TSH every four weeks until mid-gestation and at least once near 30 weeks in women treated for hypothyroidism.
Moderate RecLow EvidenceATA 2026ACOG PB 223 2020Check thyroid function every two to four weeks on antithyroid drugs in the first half of pregnancy and every four to eight weeks thereafter.
Moderate RecLow EvidenceATA 2026Test thyroid function at 4–6 weeks and 4–6 months postpartum after Graves disease, or sooner if symptoms return.
Moderate RecLow EvidenceATA 2026Treat the thyrotoxic phase of postpartum thyroiditis with a beta-blocker for symptoms, not with thioamides.
AgainstModerate EvidenceACOG PB 223 2020Consider levothyroxine for the hypothyroid phase when symptomatic, breastfeeding or planning another pregnancy, and review whether it can stop later.
Conditional RecLow EvidenceATA 2017Check TSH in any woman with new postpartum depression.
Moderate RecLow EvidenceACOG PB 223 2020Continue methimazole up to 20 mg/day or propylthiouracil up to 750 mg/day during breastfeeding; these doses are not expected to affect infant thyroid function.
Moderate RecLow EvidenceATA 2026| Situation | What to Check | When | Common Pitfall |
|---|---|---|---|
| On levothyroxine | TSH (free T4 if needed) | Every 4 weeks to about 20 weeks, then near 30 weeks | Forgetting to reduce the dose after delivery |
| On antithyroid drugs | Free T4 (plus T3 if T3-predominant) | Every 2–4 weeks early; 4–8 weeks after 20 weeks | Chasing a normal TSH and overtreating the fetus |
| Graves history, TRAb high | TRAb/TSI; fetal ultrasound | First trimester, 18–22 weeks, 30–34 weeks | Assuming ablated patients carry no fetal risk |
| Postpartum, after Graves or antibodies | TSH, free T4 | 6 weeks; 4–6 months; with any symptoms | Attributing fatigue or low mood to the new baby |
Evidence in Context
How the guidelines and trials on thyroid disease in pregnancy line up.
Where ACOG, ATA 2026 and RCOG Agree▾
All three reject universal screening, treat overt hypothyroidism, target a TSH below 2.5 mU/L on treatment, favour propylthiouracil in the first trimester, and advise against levothyroxine for antibodies alone. ACOG formally endorsed the 2026 ATA guideline.
Where They Differ▾
ATA 2026 permits first-trimester treatment of subclinical hypothyroidism by shared decision; RCOG clearly recommends it only above a TSH of 10 mU/L; ACOG 2020 found no evidence of benefit. ACOG judged routine iodine supplementation unproven, whereas ATA 2026 advises it for all.
What the Trials Add▾
Every large levothyroxine trial — for subclinical disease after early pregnancy or for antibodies alone — has been negative; the positive signals come from small, early-treatment studies.
Evidence Gaps
These are the open questions in thyroid disease in pregnancy that clinicians meet in practice, where current advice rests largely on observational data or consensus.
- Whether levothyroxine started early for mild thyroid disease in pregnancy in the first trimester for subclinical hypothyroidism improves any hard outcome remains untested in an adequately powered trial.
- Risk-based TSH thresholds, rather than statistical reference intervals, have not been defined.
- Whether to stay on propylthiouracil or switch to methimazole after the first trimester is unresolved.
- Optimal free T4 targets on antithyroid drugs, and how to read a fetal goitre, lack good data.
- Whether mild-to-moderate iodine deficiency harms child neurodevelopment, and whether supplementation prevents it, has not been proven in randomised trials.
References
- 1.Korevaar TIM, Leung AM, Alexander EK, et al. American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid. 2026;36(5):481-544. https://doi.org/10.1177/10507256261445624
- 2.American College of Obstetricians and Gynecologists. Thyroid disease in pregnancy: ACOG Practice Bulletin, Number 223. Obstet Gynecol. 2020;135(6):e261-e274. https://doi.org/10.1097/AOG.0000000000003893
- 3.Chan SY, Marsh MS, Gilbert J, et al. Management of thyroid disorders in pregnancy: Green-top Guideline No. 76. BJOG. 2025;132(8):e130-e161. https://doi.org/10.1111/1471-0528.18088
- 4.Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315-389. https://doi.org/10.1089/thy.2016.0457
- 5.Lazarus JH, Bestwick JP, Channon S, et al. Antenatal thyroid screening and childhood cognitive function. N Engl J Med. 2012;366(6):493-501. https://doi.org/10.1056/NEJMoa1106099
- 6.Casey BM, Thom EA, Peaceman AM, et al. Treatment of subclinical hypothyroidism or hypothyroxinemia in pregnancy. N Engl J Med. 2017;376(9):815-825. https://doi.org/10.1056/NEJMoa1606205
- 7.Dhillon-Smith RK, Middleton LJ, Sunner KK, et al. Levothyroxine in women with thyroid peroxidase antibodies before conception. N Engl J Med. 2019;380(14):1316-1325. https://doi.org/10.1056/NEJMoa1812537
- 8.Wang H, Gao H, Chi H, et al. Effect of levothyroxine on miscarriage among women with normal thyroid function and thyroid autoimmunity undergoing in vitro fertilization and embryo transfer: a randomized clinical trial. JAMA. 2017;318(22):2190-2198. https://doi.org/10.1001/jama.2017.18249
- 9.Alexander EK, Marqusee E, Lawrence J, et al. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med. 2004;351(3):241-249. https://doi.org/10.1056/NEJMoa040079
- 10.Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97(7):2396-2403. https://doi.org/10.1210/jc.2011-2860
- 11.Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. https://doi.org/10.1089/thy.2016.0229
- 12.Athanasiadou KI, Peppa M, Kalantaridou SN, Paschou SA. Navigating the RCOG 2025 and ATA 2026 guideline updates on the management of thyroid disorders during pregnancy. Case Rep Womens Health. 2026:e00827. https://doi.org/10.1016/j.crwh.2026.e00827
How to Read the Evidence Tags
Every recommendation carries a strength tag and an evidence tag — Medaptly’s own simplified reading of the underlying guidance, not a reproduction of any source body’s grading system.
| Strength Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action |
| Moderate Rec | The weight of evidence favours this action |
| Conditional Rec | The benefit is less certain — individualise |
| Against | Evidence points to no benefit or potential harm |
| Evidence Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed trials or high-quality meta-analyses |
| Moderate Evidence | A single trial or large observational dataset |
| Low Evidence | Expert consensus or small studies |